Back to News
Market Impact: 0.2
CelluPro obtient la certification EXCiPACT™ pour la fabrication de milieux de culture cellulaire conformes aux bonnes pratiques de fabrication (Good Manufacturing Practices (GMP)), renforçant ainsi ses capacités mondiales d'approvisionnement en produits issus de la biofabrication
Source: PR Newswire
Healthcare & BiotechRegulation & LegislationCompany Fundamentals
CelluPro obtained EXCiPACT GMP certification for pharmaceutical excipients, validating its quality-management standards for serum-free cell culture media and bioprocessing solutions. The certification could strengthen the biotechnology supplier's credibility with pharmaceutical customers and support commercial adoption, though the release provides no financial metrics or customer-contract details.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
moderately positive
Sentiment Score
0.45
More News
- OpenAI Trims Target Value & Volvo Cars Cuts 2,500 Jobs
- PG&E’s CEO says AI is ‘the best thing that could’ve ever happened to the grid’
- Defense giant Saab sees orders triple after Gripen fighter jet deal with Ukraine
- Volvo Cars shares plunge 25% amid China sales slump and fresh job cuts
- Mark Zuckerberg owns 13% of Meta but controls 61% of its votes. California’s wealth tax would bill him on the 13%
- Eni Raises Investor Payouts as High Fuel Prices Boost Cash Flow
From AllMind Research
- Anthropic IPO Preview: Valuation, Timing, and What to Watch
- Shein After the IPO: Venue, Valuation, and What Must Be Proved
- What AI Research Tools Should a Small Hedge Fund Buy First?
- AI Tools for Family Offices: A Stack by Decision Type
- Reading Conviction in the Tape: What Level 3 Order Book Data Really Tells Discretionary PMs